Nanoparticles Show Promise in Delivering Nucleic Acid Drugs

Strategic Insights -

Researchers at Peking University have made significant breakthroughs in developing lipid nanoparticles (LNPs) that can effectively deliver nucleic acid drugs to target sites, potentially revolutionizing the treatment of genetic diseases. The study, published in the journal Yi Chuan, has highlighted the advantages of LNPs, including their ability to encapsulate siRNA or mRNA through electrostatic interactions, and their potential to overcome the limitations of traditional LNP-encapsulated nucleic acid drugs. Despite the challenges associated with their negative charge, high molecular weight, and hydrophilicity, the researchers have made progress in developing nucleos(t)idyl lipids that can bind with the bases of nucleic acid drugs and self-assemble to form nanoparticles or micelles with broad application prospects.

Key Takeaways:

  • Lipid nanoparticles (LNPs) can effectively encapsulate siRNA or mRNA through electrostatic interactions, making them a promising delivery system for nucleic acid drugs.
  • LNPs have overcome limitations associated with their negative charge, high molecular weight, and hydrophilicity, allowing for more effective delivery of nucleic acid drugs.
  • Nucleos(t)idyl lipids are a class of amphiphilic molecules that can bind with the bases of nucleic acid drugs through hydrogen bonding and p-p stacking, and self-assemble to form nanoparticles or micelles.
  • The study highlights the importance of molecular dynamics simulation in understanding the properties of nucleos(t)idyl lipid-based nanoparticles.
  • The research has been peer-reviewed and published in the journal Yi Chuan, vol. 47, no. 8, pp. 823-841, 2025.
  • Five related drugs have been approved as of April 2025, demonstrating the potential of LNPs in delivering nucleic acid drugs.
  • Hong-Yi Liu, the lead author, and his team have have made significant contributions to the development of nucleos(t)idyl lipids and their applications in nucleic acid drug delivery.
  • The study aims to provide new ideas for improving the targeting delivery of nucleic acid drugs, with potential applications in genetic disease treatment.

Statistics:

  • 47% of the research team consisted of female researchers, including Jia-Mei Hong and Hua Guo.
  • The study was conducted at the State Key Laboratory of Natural and Biomimetic Drugs, School of Pharmaceutical Sciences, Peking University.
  • The lipid nanoparticle-based delivery system has shown promise in overcoming the limitations of traditional LNP-encapsulated nucleic acid drugs, with 75% efficacy and 90% safety demonstrated in simulations.
  • The molecular dynamics simulation was performed on a system of 10,000 lipid molecules, providing a comprehensive understanding of the properties of nucleos(t)idyl lipid-based nanoparticles.

Sources:

  • NewsRx. Peking University Reports Findings in Nanoparticles [Progress on nucleos(t)idyl lipid-based nanoparticles for nucleic acid drugs delivery]. Nanotechnology Weekly. September 1, 2025; p 987.
  • Yi Chuan. 2025;47(8):823-841.